A phase 1/2 monotherapy evaluating AFM24 in 14 heavily treated EGFR mutant NSCLC patients showed a DCR of 50% and a median duration of therapy of 6.7 weeks (1.0–26.1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.